Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Yu Narusov

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Kardiologiia|December 31, 2019
[Soluble ST2 - biomarker for prognosis and monitoring in decompensated heart failure]A A Skvortsov, O Yu Narusov, M D Muksinova
Vestnik Rentgenologii I Radiologii|November 11, 2015
[Phantom kidney at angionephroscintigraphy]S P Mironov, V B Sergienko, O Yu Narusov, et al.
Kardiologiia|March 16, 2017
[The Role of Markers of Organ Damage in Patients With Chronic Heart Failure]D E Koshkina, A A Skvortsov, V N Protasov, et al.
Kardiologiia|March 15, 2017
[Therapy of High Risk Patients After Decompensation of Heart Failure Under NT-proBNP Control. Main Results]A A Skvortsov, D E Koshkina, O Yu Narusov, et al.
Kardiologiia|March 15, 2017
[Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation]A A Skvortsov, V N Protasov, O Yu Narusov, et al.
Kardiologiia|December 29, 2023
The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart FailureM D Muksinova, O Yu Narusov, A V Sychev, et al.
Kardiologiia|January 10, 2019
A A Skvortsov, O Yu Narusov, M D Muksinova, et al.
Kardiologiia|November 13, 2019
Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure DecompensationA A Skvortsov, Vladimir N Protasov, O Yu Narusov, et al.
Kardiologiia|February 2, 2019
V N Protasov, O Yu Narusov, A A Skvortsov, et al.
Kardiologiia|February 16, 2022
[Experience of complex application of cardiac contractility modulation by Optimizer Smart System and endovascular mitral valve repair by the MitraClip System in the treatment of heart failure]Yu Sh Sharapova, T M Uskach, O Yu Narusov, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Kardiologiia|December 31, 2019
[Soluble ST2 - biomarker for prognosis and monitoring in decompensated heart failure]A A Skvortsov, O Yu Narusov, M D Muksinova
Vestnik Rentgenologii I Radiologii|November 11, 2015
[Phantom kidney at angionephroscintigraphy]S P Mironov, V B Sergienko, O Yu Narusov, et al.
Kardiologiia|March 16, 2017
[The Role of Markers of Organ Damage in Patients With Chronic Heart Failure]D E Koshkina, A A Skvortsov, V N Protasov, et al.
Kardiologiia|March 15, 2017
[Therapy of High Risk Patients After Decompensation of Heart Failure Under NT-proBNP Control. Main Results]A A Skvortsov, D E Koshkina, O Yu Narusov, et al.
Kardiologiia|March 15, 2017
[Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation]A A Skvortsov, V N Protasov, O Yu Narusov, et al.
Kardiologiia|December 29, 2023
The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart FailureM D Muksinova, O Yu Narusov, A V Sychev, et al.
Kardiologiia|January 10, 2019
A A Skvortsov, O Yu Narusov, M D Muksinova, et al.
Kardiologiia|November 13, 2019
Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure DecompensationA A Skvortsov, Vladimir N Protasov, O Yu Narusov, et al.
Kardiologiia|February 2, 2019
V N Protasov, O Yu Narusov, A A Skvortsov, et al.
Kardiologiia|February 16, 2022
[Experience of complex application of cardiac contractility modulation by Optimizer Smart System and endovascular mitral valve repair by the MitraClip System in the treatment of heart failure]Yu Sh Sharapova, T M Uskach, O Yu Narusov, et al.
Pageof 2